NAMSA Begins Next Chapter of Growth under Newly Appointed CEO, Dr. Christophe Berthoux
TOLEDO, Ohio–(BUSINESS WIRE)–NAMSA®, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its executive leadership transition plan with the appointment of Dr. Christophe Berthoux as NAMSA’s new CEO, effective March 22, 2021. Dr. Berthoux most recently served as CEO of Synexus Clinical Research Limited and currently acts as an Operating Partner of private equity healthcare firm, ArchiMed, who acquired majority stake in NAMSA in September 2020.
Following this transition former President and CEO, John Gorski, will relinquish day-to-day operations to focus on strategy and serve as the Vice Chair of NAMSA’s Board of Directors. Commenting on this change, Mr. Gorski stated, “Although my desire is to step down as CEO after fully committing 15 years as its leader, my heart is with NAMSA and I will continue to be involved in a meaningful way. Dr. Berthoux possesses the expertise and vision for NAMSA’s future goals, and has the talent and drive to lead us forward. I look forward to working more closely with our Board of Directors to provide support to Christophe as he builds upon NAMSA’s marketplace position as the CRO leader in the medical device industry,” Gorski concluded.
“I am thrilled to be joining NAMSA’s global team,” commented Christophe. “I believe NAMSA has a great business model and talented management team that uniquely positions it to capitalize on the dynamic medtech development environment. As the industry continues to look for trusted partners to enable the development of life-saving technologies, I believe NAMSA is leading the way in providing robust and proven development solutions for Sponsors across the globe,” Berthoux concluded.
Core to NAMSA’s executive leadership transition plan is also the appointment of Nadim Yared as NAMSA’s new Board of Directors Chairman. Yared, previously serving as President and CEO of medical device firm CVRx and Chairman of AdvaMed, developed and commercialized the world’s first neuromodulation device for the treatment of chronic heart failure (BAROSTIM NEO).
Remarking on these significant and exciting changes for NAMSA, Denis Ribon, ArchiMed’s Chairman commented, “These leadership appointments solidify the aggressive growth strategy we have put in motion at NAMSA. We have much to gain from these transitions, as do global Sponsors as we provide them with proven solutions to achieve cost-effective, efficient commercialization of innovative medical technologies. Together, we will make an even greater impact on patient outcomes and advancing healthcare worldwide,” Ribon concluded.
About NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services; NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com
Contacts
NAMSA Media:
Leah Davidson, MA, MBA
Global Manager, Marketing Communications
[email protected]
